Access Vascular has developed a proprietary biomaterial platform that is both hydrophilic and lubricious, and has incorporated this material into two commercially-available venous access devices, the HydroPICC® Peripherally Inserted Central Catheter and HydroMID™ Midline Catheter. In vitro studies have shown that this biomaterial technology results in an average of 97% less thrombus accumulation on its surface compared to a standard polyurethane catheter.*

Access Vascular, Inc. today announced it has received FDA clearance for the second generation of its HydroPICCTM peripherally inserted central catheter (PICC), which has demonstrated an average of 97% less thrombus accumulation on its surface compared to a standard polyurethane catheter1.

Access Vascular, a medical device company developing the next generation of intravenous devices from novel biomaterials designed to minimize the risk of bloodstream infection, catheter thrombosis, and vein trauma, announced $6M in new funding from new and existing investors. With this new round, Access Vascular is poised to launch the next generation of its FDA-cleared HydroPICC device, initiate the company's first post-market registry study, and expedite new product development.

Access Vascular, Inc. has been awarded a group purchasing agreement for a Breakthrough Technology contract with Premier. Effective September 1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the HydroPICC™ peripherally inserted central catheter which is indicated for reduced thrombus accumulation. In benchtop studies, HydroPICC has demonstrated a 97% reduction in thrombus accumulation compared to traditional polyurethane PICCs.

Earlier this year, Access Vascular’s HydroPICC device was first used in patients at Riverside Medical Center in Kankakee, IL. HydroPICC represents a new option for clinicians to address catheter-related thrombosis, and upcoming field evaluations of the device will seek to establish our new hydrogel material platform as the preferred option for venous access.

Access Vascular is pleased to announce the publication of head-to-head in vitro tip occlusion results comparing HydroPICC with the market leading catheter, PowerPICC (Becton Dickinson). In in vitro blood flow loop testing, HydroPICC exhibited a complete reduction in thrombotic occlusion rate when compared to the PowerPICC catheter.

Access Vascular had the opportunity to host Dr. Jeffrey Chick and Dr. Arun Jagannathan at the company’s booth at the Society of Interventional Radiology 2019 conference for an engaging discussion on difficult venous access. The podcast was hosted by BackTable podcast, a premier source for information on tools and techniques for interventional radiologists.

Riverside Medical Center became the first hospital to implant Access Vascular’s HydroPICC peripherally inserted central catheter (PICC). The device is designed from a novel biomaterial created to address the most common and costly complications plaguing the global venous access market.

Access Vascular has published the results of in-vitro and in-vivo studies of HydroPICC. HydroPICC showed an an average of 97% less thrombus accumulation on its surface (based on platelet count)* compared to a standard polyurethane catheter.

MassDevice: Access Vascular, a medical device company reinventing venous access using proprietary material technology designed to reduce thrombus accumulation, announced today that the Company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its lead product.